Research indicates that in ATLL patients exhibiting this response to nivolumab, amplification of all major clones harboring diverse mutations suggests that rapid ATLL expansion following PD-1 blockade reflects an unexpected loss of ATLL suppression rather than a selective advantage for specific clones (95). The gene discussed is RPL17; the disease is adult T-cell leukemia/lymphoma.